Funded Projects

Priority Projects
Small Projects
HICT Endorsed Trials

Priority Projects

Title

Lead PI

Biomarkers to Aid Treatment Decision Making in Early Stage Breast Cancer in Ontario

Mark Levine, McMaster University

Companion Circulating Tumour Cells Analysis to NCIC-CTG Clinical Trial

Jeremy Squire, Queen’s University

Circulating Tumor Cell analysis and characterization using novel microfiltration technology and FISH: A correlative biology companion study to the NCIC CTG Phase II Clinical Trial IND.205

Alison Allan, London Health Sciences Centre Research Inc.

Quantifying the Effect of Notch Inhibition on Tumour-Initiating Cells of Gamma-Secretase Inhibitor (RO4929097) in Advanced, Triple Negative Breast Cancer and Other Solid Tumours

Michael Reedijk, University Health Network

Multi-Institution Study of DCE CT Imaging Biomarkers of Tumours Microvasculature in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib

Masoom Haider, University Health Network

A Pilot Study of BOLD MRI and FLT-PET in Patients with Locally Advanced Breast Cancer Undergoing Neoadjuvant Chemotherapy

Mark Levine, McMaster University

Imaging with 111In-Pertuzumab to predict response to Trastuzumab in HER2 Positive Metastatic Breast Cancer

Mark Levine, McMaster University

Genomics Path Study Feasibility Project

Lillian Siu, University Health Network

A Phase II Study of Sunitinib or Temsirolimus in Patients with Advanced Rare Tumours

Elizabeth Eisenhauer, Queen’s University

Back to top

Small Projects

Title Lead PI, Institution Award Total Award Period

Translating the clinical utility of cancer microparticle enumeration and functional tumor imaging for combined prognosis of colorectal cancer

Barbara Fisher, Lawson Health Research Institute

$58,840

July 2012 - March 2013

Stem Cell Gene Expression Signatures in Clinical Pancreatic Cancer

Neesha Dhani, University Health Network

$61,219.34

July 2012 - March 2013

Correlation of Baseline Biomarker Levels with Clinical Outcomes and Response to Zactima in Bone Metastatic Breast Cancer Patients

Christina Addison, Ottawa Hospital Research Institute

$41,343.20

July 2012 - March 2013

Genomic profiling of circulating tumor cells (CTCs): a feasibility study

Alison Allan, Lawson Health Research Institute

$44,842.88

Jan 2012 – June 2012

Molecular Determinants of Outcome with mTOR Inhibition in Endometrial Cancer

Amit Oza, University Health Network

$68,789.63

October 2011 – March 2012

Companion Pharmacogenetic Study in the Ovarian Cancer ICON7 Trial

Helen Mackay, University Health Network

$100,000

October 2011 – March 2012

Evaluation of Correlative Biomarkers in Cervical Cancer Patients Treated with Temsirolimus, an Inhibitor of Mammalian Target of Rapamycin (mTOR)

Elizabeth Eisenhauer, Queen’s University

$55,140

October 2011 – March 2012

Identification and Validation of Plasma Biomarkers that Predict Response to Cediranib in Non-Small Cell Lung Cancer Patients

Christina Addison, Ottawa Hospital Research Institute

$70,696

October 2011 – March 2012

Companion Pharmacogenetic Study of BR.24

Geoffrey Liu, University Health Network

$88,140

October 2010 – March 2011

Drug Level Analysis Technologies for Personalized Cancer Therapy and High Impact Clinical Trial

Richard Kim, Lawson Health Research Institute

$102,097.50

October 2010 – March 2011

Integrated Molecular Profiling of Patient derived Tumour Xenograft Models for Preclinical Evaluation of Targeted Drugs and Biomarker Discoveries

Lillian Siu, University Health Network

$104,455

October 2010 – March 2011

Data Acquisition module for Real-Time Quantitative Ultrasound of neoadjuvant Chemotherapy Response Assessment

Gregory Czarnota, Sunnybrook Health Sciences Centre

$51,705

October 2010 – March 2011

Back to top

HICT Endorsed Trials

Title

Lead PI

TRT Site

Award Total

Award Period

Non-Invasive staging of prostate cancer: detection of circulating prostate microparticles using unique metastasis-specific antibody 1A5

Hon Leong

Lawson Health Research Institute

$5,544.00

October 2012 - September 2013

Prospective Identification of Risk Factors for Skeletal Related Events in Breast Cancer Patients Receiving Bisphosphonates for Bone Metastases. PROVIST 2

Mark Clemons

Ottawa Hospital Research Institute

$59,074.00

October 2012 - September 2013

ADMA as a Biomarker for Tumour Response, Overall Survival and Toxicities Related to Cediranib Treatment in Non-Small Cell Lung Cancer Patients in NCIC CTG BR.24

Glenwood Goss

Ottawa Hospital Research Institute

$55,490.00

October 2012 - September 2013

Exploratory analyses to evaluate potential biomarkers of resistance and response to single agent cabozatinib treatment in endometrial cancer – correlative studies on PHL-086 (pending)

Amit Oza

University Health Network

$50,026.21

October 2012 - September 2013

A Phase II Study of Ipilimumab in women with metastatic or recurrent HPV-related cervical carcinoma of either squamous cell or adenocarcinoma histologies

Amit Oza

University Health Network

$42,639.92

October 2012 - September 2013

A Phase II Single Arm Study Of AUY922 In patients with metastatic pancreatic adenocarcinoma who are resistant to first line chemotherapy

Malcolm Moore

University Health Network

$15,925

October 2011 – September 2012

A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer

Pamela Goodwin

University Health Network

$15,925

October 2011 – September 2012

A Phase II Study of AZD0530 as first line treatment in patients with metastatic or locally advanced gastric carcinoma

Helen MacKay

University Health Network

$9,403.33

October 2011 – September 2012

A Phase II Study of AZD0530 in patients with advanced, recurrent non-small cell lung cancer who have previously received platinum-based combination chemotherapy

Natasha Leighl

University Health Network

$9,403.33

October 2011 – September 2012

A Phase II Study of AZD0530 in Recurrent or Metastatic Soft Tissue Sarcoma

Margaret Von Mehren

University Health Network

$9,403.33

October 2011 – September 2012

A Phase II Study of GW786034 (Pazopanib) with or without Bicalutamide in Hormone Refractory Prostate Cancer

Amit Oza

University Health Network

$7,866.66

October 2011 – September 2012

The Role of VEGF-A Signaling in Maintenance of the Glomerular Filtration Barrier and Blood Pressure

Malcolm Moore

University Health Network

$7,866.66

October 2011 – September 2012

A phase I study of R04929097 in combination with gemcitabine in patients with advanced solid tumors

Phillipe Bedard

University Health Network

$7,866.66

October 2011 – September 2012

Randomized Phase III Study of Optimal Sequencing of Hormonal Therapy and Radiation in Patients with T1-T3 Prostate Cancer (OTT-01-01)

Shawn Malone

Ottawa Hospital Research Institute

$12,800

April 2011 – September 2011

A Multicentre Study Assessing 12-Weekly Intravenous Bisphosphonate Therapy in Women with Low Risk Bone Metastases from Breast Cancer using Bone Resorption Markers (ER 10-04, TRIUMPH)

Mark Clemons

Ottawa Hospital Research Institute

$59,124

April 2011 – September 2012

A Phase I Dose Finding Study of the Combination of High-Dose Statin Agent (Rosuvastatin) with Erlotinib in Patients with Advanced Solid Malignancies with a Focus on Squamous Cell Carcinomas and NSCLC (OTT-08-07)

Glen Goss

Ottawa Hospital Research Institute

$68,848

April 2011 – September 2012

A Phase I study of various administration schedules of RO4929097 with multiparameter assessment (biomarkers, pharmacokinetics, pharmacodynamics) in patients with advanced solid tumours

Sebastien Hotte

McMaster University

$20,305

October 2011 – September 2012

Randomised Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients with High Risk, Clinically Localized Prostate Cancer

Joseph Chin

Lawson Health Research Institute

$30,360

October 2011 - September 2012

Back to top